Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03837405
Other study ID # 4R33AT009333
Secondary ID 4R33AT009333
Status Completed
Phase N/A
First received
Last updated
Start date December 12, 2018
Est. completion date June 17, 2021

Study information

Verified date June 2021
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators plan an R33 phase trial in which 120 persons with type 2 diabetes (T2DM) will be randomized (using a 1:1 ratio) to education alone (Ed) on following a carbohydrate restricted diet for T2DM, or this same education content with added mindful eating/Mindfulness-Based Intervention components (Ed+MBI).


Description:

The investigators will randomize 120 persons with T2DM in a 1:1 ratio to a nutrition education alone arm (Ed n=60) vs. a nutrition education with mindfulness-based intervention components (Ed+MBI n=60) arm and follow them for 12 months. The interventions will be provided in a weekly group setting, with about 10 to 12 persons per group. Some educational intervention components will be delivered using a smartphone app. After the 12-week initial intervention, the investigators will re-randomize participants using an adaptive intervention design to receive low, medium, or high intensity maintenance training, depending on level of adherence achieved during the initial intervention period. Follow-up assessments will be performed at 3, 6, 9, and 12 months. The investigators will address the following specific aims: 1. Test the hypothesis that the Ed+MBI arm will have better dietary adherence than the Ed arm. 2. Test whether our proposed behavioral mechanisms (e.g. decreased eating in response to cravings or difficult emotions) predict dietary adherence. 3. Compare randomized arms in the adaptive maintenance intervention design to optimize maintenance phase dosing in future trials. 4. Obtain preliminary assessment of intervention effects on clinical outcomes This is the second phase of a two-phase study. Pilot testing has been completed in the first phase (R61). The second phase (R33) will include employing an adaptive intervention design in the post-treatment phase to test optimization of the maintenance intervention (i.e. assigning maintenance intensity/dose based on how a participant is doing). The investigators will use fingerstick blood ketone measures, which provide an objective measure of whether the target levels of carbohydrate restriction have been attained, as our primary adherence outcome measure. This will be supplemented by 24-hour diet recall measures of carbohydrate consumption. Important secondary outcome measures will include clinical measures such as glycosylated hemoglobin and behavioral measures such as frequency of eating in response to food cravings.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date June 17, 2021
Est. primary completion date June 17, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. History of T2DM mellitus. 2. HbA1c = 6.5% and < 12.0% at screening. 3. Experience food-related cravings most days of the week and eat in response to these cravings regularly. 4. Aged 18 years old and older. 5. Able to engage in light physical activity. 6. Willing and able to participate in the interventions including appropriate participation in the group setting. 7. Have smartphone and are willing to use it on a regular basis for data collection. 8. Ability to speak English. Exclusion Criteria: 1. Unable to provide informed consent. 2. A substance abuse, mental health, or medical condition that, in the opinion of investigators, will make it difficult for the potential participant to participate in the intervention, that may need immediate changes in medical management that will affect study outcome measures, or that may require important adaptations in the study diet. 3. Pregnant or planning to get pregnant in the next 12 months, breastfeeding or less than 6 months post-partum. 4. Current use of weight loss medications, such as Alli or amphetamine-based drugs that may affect weight. 5. Planned or history of weight-loss (bariatric) surgery, or other intestinal surgeries that cause malabsorption. These are likely to change study outcome measures, making it difficult to distinguish the effects of the intervention program, or require extensive tailoring of the diet intervention. 6. Currently enrolled in a weight loss program, such as Weight Watchers or a self-help group such as Overeaters Anonymous, or have unalterable plans to enroll in one of these programs in the next year; using a ketogenic low carbohydrate diet in the past 6 months with advice from a health care professional; or use of a mindful eating program with guidance from a professional in the past 6 months or have ever used the study mindful-eating app. 7. Vegan or vegetarian. 8. Unwilling to do regular blood testing at home for glucose or ketone monitoring.

Study Design


Intervention

Behavioral:
Carbohydrate-restricted diet
Education for carbohydrate-restricted diet
Mindfuless
Mindful eating app use plus group sessions to learn mindfulness

Locations

Country Name City State
United States Osher Center for Integrative Medicine San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Francisco National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other stress-related eating change in stress-related eating as measured by two questions about stress-related eating from the MIDUS study and one additional stress-related eating question change from baseline to 12 months
Other Perceived Stress change in Perceived Stress Scale total score change from baseline to 12 months
Other Insulin resistance Homeostatic model assessment (HOMA) index of insulin resistance (computed from insulin and fasting glucose measures) change from baseline to 12 months
Other Glycemic control--fasting glucose fasting blood glucose change from baseline to 12 months
Other Mindfulness Five-factor mindfulness scale change from baseline to 12 months
Primary diet adherence between intervention arms as measured by ketones proportion of ketone measures dichotomized as > or = 0.3 mmol/L versus < 0.3 measures from ketone measure initiation (week 5) to 12 months
Primary diet adherence between intervention arms as measured by 24- hour diet recall--dichotomous proportion of participants consuming < 50 grams/day of non-fiber carbohydrate (from 24-hour diet recall) from 3 to 12 months
Secondary executive functioning /decreased impulsivity-Delayed Discounting change in Delayed Discounting task score change from baseline to 12 months
Secondary emotion-related eating change in emotion-related eating as measured by the Coping subscale of the Palatable Eating Motives Scale (PEMS). change from baseline to 12 months
Secondary Glycemic control--a1c hemoglobin a1c change from baseline to 12 months
Secondary frequency of eating in response to cravings frequency of eating in response to cravings using ecological momentary assessment (EMA) change from baseline to 12 months
Secondary diet adherence between intervention arms as measured by 24- hour diet recall--total carbs, continuous mean grams of non-fiber carbohydrate consumed per day (from 24-hour diet recall) from 3 to 12 months
Secondary executive functioning /decreased impulsivity--Relative Reinforcing Value of Food (RRVF) change in RRVF score change from baseline to 12 months
Secondary Salzburg Stress Eating Scale change in stress-related eating as measured by Salzburg Stress Eating Scale change from baseline to 12 months
Secondary dietary resilience (resumption of dietary adherence) after dietary non-adherence occurs time from a ketone measure of < 0.3 mmol/L to higher levels of >/= 0.3 mmol/L 12 months
Secondary Weight change pounds change from baseline to 12 months
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance